SCHEMBL23217832

SCHEMBL23217832

CCOC(=O)C(Br)c1cc(Br)c2occc2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.35
L3MBTL1 Q9Y468 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MMP8 P22894 2/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
PRNP P04156 1/20 0.33
MAPT P10636 4/20 0.33
POLB P06746 3/20 0.33
HSD17B10 Q99714 3/20 0.33
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 3/20 0.32
MAPK1 P28482 3/20 0.32
TP53 P04637 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
HTT P42858 2/20 0.32
APAF1 O14727 1/20 0.32
NPC1 O15118 1/20 0.32
USP2 O75604 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30010699 1.00 MAOB (0.35) MAOBL3MBTL1SMN1; SMN2MMP8MEN1
SCHEMBL31026070 0.77 ALDH1A1 (0.46) MAOBMEN1KMT2APRNPMAPT
SCHEMBL23217544 0.77 ALDH1A1 (0.46) MAOBMEN1KMT2APRNPMAPT
SCHEMBL23217674 0.75 SMN1; SMN2 (0.39) MAOBL3MBTL1SMN1; SMN2MAPTALDH1A1
SCHEMBL23217708 0.74 HPGD (0.40) L3MBTL1SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL29672991 0.74 HPGD (0.40) L3MBTL1SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL30010940 0.73 TBXAS1 (0.38) L3MBTL1SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL23217611 0.73 TBXAS1 (0.38) L3MBTL1SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL23217501 0.72 UGT2B7 (0.38) MAPTPOLBHSD17B10KDM4EMAPK1
SCHEMBL31147752 0.72 MMP8 (0.37) MAOBMMP8MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-09-04 US disclosed
EP-4041717-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114555570-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-27 CN disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB MAOB 438/4885L3MBTL1 4688/4885SMN1; SMN2 3788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.